Slide 1: Ampligen's potential role as a prophylactic and/or early-onset antiviral treatment for Ebola virus disease
it, a) NYSE American: AIM —_ - aimimmuno.com SS AIM ImmunoTech rm) Ampligen’s potential role as a prophylactic and/or an early-onset antiviral treatment for Ebola virus disease June 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements =" Qaim
Slide 3: Late-stage clinical immuno-pharma company
S AIM ImmunoTech We are a late-stage clinical immuno-pharma company focused on developing therapeutics across a number of disease areas, from immuno-oncology to immune disorders to viral diseases
Slide 4: Rintatolimod's (Ampligen) Excellent Safety Profile
Rintatolimod’s (Ampligen) Excellent Safety Profile 4 Qaim
Slide 5: Safety, tolerability and biological activity of repeated intranasal administration of Ampligen in healthy subjects
Safety, tolerability and biological activity of fepeated intranasal administration of Ampligen in healthy. subjects Conclusion: Repeated intranasal administration of rintatolimod every other day was well-tolerated in all tested dose levels
Slide 6: Ebola Orphan Drug Designations
Ebola Orphan Drug Designations oe Qaim
Slide 7: Ebola virus disease: In vivo protection provided by the PAMP restricted TLR3 agonist rintatolimod
“Ebola virus disease: /n vivo protection provided by the-PAMP restricted TLR3 agonist rintatolimod and its mechanism of action” Corona, et al. Antiviral Research 212 (April 2023): 105554
Slide 8: USAMRIID, 2015: Evaluating efficacy of Ampligen in mouse model of EBOV infection
USAMRIID, 2015 Evaluating the efficacy of Ampligen in mouse model of EBOV infection Study Design Z Groups Mice# Ti Dose Ti Route Ti i Mice 1 10 saline saline IP 2 10 Ampligen 6 mg/kg IP SID; +4 hr, +2, +4, +6, | Monitor weight and 3 10 Ampligen 12 mg/kg IP +8, +10, +12 days survival for 21 days 4 10
Slide 9: USAMRIID, 2015: Results
USAMRIID, 2015 ; Evaluating the efficacy of Ampligen in mousesmode! of EBOV infection Results 100 \ R ‘ 75 —*- Control z —+Control 2 - = Ampligen (6 mg/ke) = 100 —m-Ampligen (6 mg/kg) 2 —*- Ampligen (12 mg/kg) a=) <t-Ampligen (12 mg/kg) xz ——Ampligen (18 mg/kg) 5 ——Ampligen (18 mg/kg) 25 50 i) 7 + e
Slide 10: aimimmuno.com
it, a) NYSE American: AIM —_ - aimimmuno.com SS AIM ImmunoTech rm) Ampligen’s potential role as a prophylactic and/or an early-onset antiviral treatment for Ebola virus disease June 2026